Harmony Biosciences Holdings HRMY 深 滬
等待開盤 07-18 09:30:00 美东时间
36.43
+1.220
+3.46%
華盛通- 最 高36.71
- 今 開35.00
- 成交量 62.43万股
- 最 低 34.69
- 昨 收 35.21
- 總市值 20.92亿
- 52周最高 41.61
- 市盈率 靜 14.49
- 換手率 1.09%
- 52周最低 26.47
- 委 比 57.19%
- 總股本 5742.43万
- 歷史最高 62.085
- 量 比 1.23
- 振 幅 5.74%
- 歷史最低 18.6112
- 每 手 1
- 風險率 3.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Deutsche Bank Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $55
Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and raises the price target from $54 to $55.
07-11 02:17
Harmony Biosciences Reveals Promising Preclinical Data for BP1.15205
Harmony Biosciences Holdings ( ($HRMY) ) just unveiled an update. On June 11, 2...
06-11 20:47
Harmony Biosciences, Lupin reach agreement on Wakix generic launch
Lupin can launch a generic version of Harmony Biosciences' (NASDAQ:HRMY) Wakix (pitolisant) in January 2030 under a settlement agreement. The agreement resolves patent infringement litigation filed by...
06-05 22:54
Harmony Biosciences Settles Patent Dispute with Lupin
Harmony Biosciences Holdings ( ($HRMY) ) has issued an update. On June 5, 2025,...
06-05 20:58
美股大行评级 | 潜在涨幅417.8%！RBC Capital上调Perspective Therapeutics目标价至16美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136940401951563776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Perspective Therapeutics(CATX)"跑赢大市"评级，目标价从15美元升至16美元</p> <p>• Canaccord Genuity：维持Taysha Gene Th
06-04 08:35
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
Where Harmony Biosciences Hldgs Stands With Analysts
Providing a diverse range of perspectives from bullish to bearish, 9 analysts h...
06-03 02:01
Oppenheimer Assumes Harmony Biosciences Hldgs at Outperform, Announces Price Target of $61
Oppenheimer analyst Andreas Argyrides assumes Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $61.
06-03 01:16
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
